New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone!
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"The Evidence Based Rheumatology Podcast","authorlink":""},"src":"https:\/\/mcdn.podbean.com\/mf\/web\/k396tk8uzna7wkbm\/e117.mp3","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202211\/633496-0633-b9b6-7f2bb9_800.jpg"},"title":"E117: Inebilizumab for IgG4-RD (MITIGATE)","link":"javascript:;","id":"item-194125074"}]